OCT 16, 2013 12:00 PM PDT

New therapeutic strategies and new modes of drug resistance: From the bench to bedside and back again with the oncogene eIF4E

C.E. Credits: CE
Speaker
  • Principal Investigator, Structure and Function of the Cell Nucleus research unit, Full Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Instit
    BIOGRAPHY

Abstract

The eukaryotic translation initiation factor eIF4E is a potent oncogene estimated to be elevated in about 30% of human cancers including cancers of the breast, prostate, lung, colon as well as others. eIF4E is also elevated in hematological malignancies including M4 and M5 subtypes of acute myeloid leukemia (AML). eIF4E overexpression leads to oncogenic transformaiton in cell lines and to tumours in animal models. eIF4E plays critical roles in mRNA metabolism via its interactions with the methyl-7 guanosine (m7G) cap on the 5 end of mRNAs. eIF4E is best known for its role in mRNA translation but also plays roles in the export of mRNAs from the nucleus to the cytoplasm. Both of these functions are relevant to its oncogenic potential. New findings will be discussed with regard to newly defined roles of eIF4E in mRNA export. In particular, the ability of eIF4E to modulate the nuclear pore complex (NPC) in order to enhance the export function of eIF4E. In fact, these studies directly link its transformation capacity to its ability to modulate export of certain mRNAs. Further, these studies demonstrate that certain component of the NPC can suppress eIF4E mediated transformation. Finally, the clinical findings targeting eIF4E activity will be discussed. Our studies, including new NMR studies show that ribavirin directly binds the m7G cap-binding pocket of eIF4E. Ribavirin represses eIF4E dependent mRNA translation and mRNA export. In a Phase II clinical trial, ribavirin monothreapy treatment led to targeting of eIF4E activity in M4 /M5 AML patients and this correlated to clinical responses in patients. In an ongoing Phase I trial with ribavirin combined with cytarabine, eIF4E targeting and clinical responses have also been observed. Thus targeting eIF4E activity appears beneficial to patients. Learner Objectives: *Discuss the importance and possibility of targeting eIF4E in cancer *Discuss new mechanisms by which eIF4E can, in part, transform cells


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
APR 22, 2021 5:00 PM CEST
APR 22, 2021 5:00 PM CEST
Date: April 22, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) System transcriptomics of the schizophrenia brain - Phillip Khaitovich Schizophrenia tops the psychiatric disorder l...
JUL 28, 2021 8:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
JUL 28, 2021 8:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: July 28, 2021 Time: 8:00am PDT Breast cancer is the most common form of cancer in women. It is estimated that 1 out of 8 women in the US will develop invasive breast cancer during her...
OCT 16, 2013 12:00 PM PDT

New therapeutic strategies and new modes of drug resistance: From the bench to bedside and back again with the oncogene eIF4E

C.E. Credits: CE

Specialty

Biochemistry

Drug Discovery

Cancer Research

Immunology

Cancer Therapeutics

Molecular Biology

Cell Biology

Geography

North America100%

Registration Source

Website Visitors100%

Job Title

Educator/Faculty100%

Organization

Academic Institution100%


Show Resources
Loading Comments...
Show Resources
Attendees
  • See more